EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Nano-based therapy for type 1 diabetes: from immuno-intervention to insulin delivery

Huiwen Pang, Zhuo Chen, Felicity Y Han

Acta Biomaterialia · 2025

DOI: 10.1016/j.actbio.2025.06.016 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Acta Biomaterialia, 2025. Verfasst von Huiwen Pang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin, Drug Delivery Systems, Immunotherapy. Die Arbeit nennt 245 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Sponsorship Council, University of Queensland, China Scholarship Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Type 1 diabetes (T1D) is a chronic autoimmune disease in which the immune system mistakenly attacks and destroys insulin-producing β-cells in the pancreas, causing an absolute insulin deficiency. While traditional treatments, such as insulin replacement therapy, can alleviate symptoms, they fail to halt disease progression fundamentally. Recent advancements in nanotechnology have shown significant progress in treating T1D, particularly in restoring immune tolerance and enabling precise drug delivery. These innovative nano-based therapies allow researchers to better regulate immune responses and protect the remaining β-cell function. Additionally, breakthroughs in insulin delivery using nano-based systems, including oral, transdermal, and glucose-responsive insulin release delivery systems, have provided new avenues for improving glycemic control in T1D patients. Here by exploring the pathogenesis of T1D and the importance of immune tolerance with the intervention of nanotechnology, this review summarizes nano-based innovative strategies in immune intervention, including antigen, antibody and gene therapy, as well as nano-based insulin delivery systems including the to-date achievement and related challenges remaining. Developing more effective nano-based therapeutic approaches for T1D holds big promise. STATEMENT OF SIGNIFICANCE: T1D remains a significant clinical challenge due to its autoimmune nature and the lifelong dependence on insulin therapy. Traditional treatments manage symptoms but do not address the underlying immune dysfunction. This review underscores the transformative potential of nanotechnology in T1D treatment by integrating immune modulation and advanced insulin delivery. Nano-based immunotherapies aim to restore immune tolerance and preserve β-cell function, tackling the root cause of the disease. At the same time, precise insulin delivery systems offer improved glycemic control with reduced patient burden. By presenting current progress and remaining challenges, this review highlights how nano-based therapies could revolutionize T1D management, offering not only better disease control but also a pathway toward long-term remission and potentially a cure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1InsulinDrug Delivery SystemsImmunotherapyNanotechnologyHumansAnimalsInsulin-Secreting CellsGenetic Therapy

Stichwörter der Autor:innen

Antigen deliveryImmune toleranceMicroneedle patchOral insulinT1D

Substanzen

Insulin

Autor:innen und Institutionen

  • Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia.
  • Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Brisbane, QLD 4072, Australia. Electronic address: f.han@uq.edu.au.

Förderung

  • China Sponsorship Council
  • University of Queensland
  • China Scholarship Council

Zitieren

APA

Pang, H., Chen, Z., & Han, F. Y. (2025). Nano-based therapy for type 1 diabetes: from immuno-intervention to insulin delivery. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2025.06.016

Vancouver

Pang H, Chen Z, Han FY. Nano-based therapy for type 1 diabetes: from immuno-intervention to insulin delivery. Acta Biomaterialia. 2025. doi:10.1016/j.actbio.2025.06.016

BibTeX
@article{Pang2025,
  author = {Pang, Huiwen and Chen, Zhuo and Han, Felicity Y},
  title = {Nano-based therapy for type 1 diabetes: from immuno-intervention to insulin delivery},
  journal = {Acta Biomaterialia},
  year = {2025},
  doi = {10.1016/j.actbio.2025.06.016}
}
Kostenlos starten →